Okoshi and colleagues 1 studied the modulatory role of neuregulin-1 on parasympathetic activity in the heart. This interesting study on isolated cardiomyocytes showed that heterozygous gene deletion of neuregulin-1 abrogated the inhibitory activity of the muscarinic cholinergic system on ␤-adrenergic signaling. Because protein levels of M 2 muscarinic receptors and G protein subunits were unchanged in neuregulin-1-deficient cardiomyocytes, the authors proposed that neuregulins support normal parasympathetic modulation of excess ␤-adrenergic stimulation of the heart.
Response
We appreciate the interest of Dr Lemmens and colleagues in our work. 1 The study by Lemmens et al 2 is important because it suggests that neuregulin-1 (NRG-1) also has a direct antiadrenergic effect. We agree that, taken together, the observations from both studies strongly suggest that the capability of the heart to counterbalance ␤-adrenergic activity is impaired when the neuregulin-erbB pathway is suppressed.
With regard to the questions raised by the investigators, available data indicate that neuregulin-1 expressed in the endocardium and microvascular endothelium mediates paracrine signaling to neighboring cardiomyocytes. 3 The downstream components of such signaling are likely to include nitric oxide synthase but are as yet incompletely understood. It is likely and plausible, however, that in the heterozygote NRG-1 ϩ/Ϫ mouse, this altered paracrine activity results in chronic changes in gene expression that are involved in the cardiac parasympathetic system signaling pathway. Such changes in gene expression would be expected to persist in the freshly isolated cardiomyocytes from the heterozygote NRG-1 ϩ/Ϫ mouse, thus leading to the observed phenotype. In our study, we did not try to rescue the carbachol-resistant NRG-1 ϩ/Ϫ phenotype with exogenous recombinant neuregulin-1. This is a fruitful line of future investigation in both in vivo and in vitro experiments.
